1034190-08-3 Usage
Uses
Used in Biochemical Research:
(S)-3-(2-amino-3-methylbutanamido)propane-1-sulfonic acid is used as a stabilizing agent for proteins and enzymes, helping to maintain their structure and function during experiments and analyses.
Used in Medical Research:
(S)-3-(2-amino-3-methylbutanamido)propane-1-sulfonic acid is used as a buffering agent in biological systems, helping to maintain a stable pH environment for various physiological processes.
Used in Pharmaceutical Development:
(S)-3-(2-amino-3-methylbutanamido)propane-1-sulfonic acid is used as a potential therapeutic agent for the treatment of various diseases, such as hypertension, cardiovascular diseases, and neurological disorders, due to its reported beneficial effects on these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1034190-08-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,4,1,9 and 0 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1034190-08:
(9*1)+(8*0)+(7*3)+(6*4)+(5*1)+(4*9)+(3*0)+(2*0)+(1*8)=103
103 % 10 = 3
So 1034190-08-3 is a valid CAS Registry Number.
1034190-08-3Relevant articles and documents
Application of isotope-enriched 3-amino-1-propanesulfonic acid and derivative thereof
-
Paragraph 0212; 0215, (2021/05/15)
The present invention relates to the use of isotopically enriched compounds of general formula I or pharmaceutically acceptable salts or esters thereof, and corresponding pharmaceutical compositions for the prevention and treatment of cerebrovascular diseases and disorders, such as vascular dementia, cerebral apoplexy, and the like. In the formula (I), R1R2X-CR2-CH2-CH2-SO3H is shown in the specification.
METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID
-
Page/Page column 42, (2008/12/06)
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.
